Selank is a synthetic peptide known in research circles primarily as an anxiolytic peptide, a compound with a studied anti-anxiety profile. This overview collects what published work says about Selank: its structure and origin, the properties under study, the likely mechanisms, the intranasal form (drops), and where the dosing data live. It is educational material about a research-use compound, not a finished medicine.

Selank: properties and origin

Selank is a heptapeptide, a synthetic analog of the endogenous peptide tuftsin (a fragment of immunoglobulin G). A stabilizing Pro-Gly-Pro sequence was added to the natural chain, which markedly extends the molecule's working time, because native tuftsin is broken down in the blood within minutes. It was developed by Russian institutes of molecular genetics and pharmacology starting in the 1990s.

The most frequently cited properties are its anxiolytic (anti-anxiety) action and a moderate nootropic effect. In preclinical and early clinical work, Selank was studied in generalized anxiety disorder and neurasthenia; some data were compared with benzodiazepines, and the authors noted the absence of pronounced sedation and withdrawal. These are study findings, not a basis for self-treatment.

Likely mechanisms of action

Selank's molecular profile is described across several directions: effects on GABAergic transmission, modulation of serotonin and other monoamine metabolism, and slowed breakdown of enkephalins through inhibition of peptidase enzymes. Some studies reported changes in BDNF expression and in the inflammatory cytokine profile. This makes Selank an interesting subject for neurobiology experiments, though no single agreed model of action exists yet.

What the studies actually showed

These mechanistic directions rest on several independent papers, and each one answers its own question. A 2001 paper showed that Semax and Selank inhibit enkephalin-degrading enzymes in human serum in vitro [1]. A 2008 paper described that intranasal Selank regulates BDNF expression in the rat hippocampus in vivo [2]. A 2019 paper in an ethanol-induced memory-impairment model in rats linked a protective effect to BDNF content in the hippocampus and prefrontal cortex [3]. None of these is a clinical protocol for humans: enzyme inhibition in vitro is not a therapeutic effect, and an animal model has its own limits of transferability.

Drops: why the intranasal form

The most common form of Selank in studies is drops (an intranasal solution, usually 0.15% or 0.3%). Peptides survive the gastrointestinal tract poorly, so oral intake is inefficient. The nasal mucosa allows fast absorption and partial access to the CNS, bypassing first-pass metabolism in the liver. That is why the literature describes Selank as nasal drops rather than tablets or capsules.

Selank in studies: where to find the dosing

In studies Selank was used mostly intranasally; the exact doses and frequency depended on the protocol. We do not present them here as instruction, the study data are collected in the reference Selank: the regimen from the clinical report.

The question of "reviews" and effects

Queries such as "selank reviews" usually look for someone else's usage experience. We do not publish such testimonials: one person's experience is not proof of an effect and says nothing about the quality of a specific batch. Something else does the work here instead, the verified identity of the compound and the published data on what was actually measured in the models. For a researcher that is a firmer basis than an anonymous review.

We supply Selank as a research substance; batches come with an independent COA. If the broader neuropeptide direction interests you, look at logically related compounds: P21 is studied as a low-molecular-weight candidate with a neurotrophic profile and effects on neurogenesis, and Pinealon, a short peptide bioregulator, is researched in the context of neuroprotection and cognitive function. Both are for research use.

The principle for research peptides is simple: batches come with a certificate of analysis (COA) in an open archive, so identity and purity can be checked before you work with the material. Here verified identity matters more than any "intake schedule."

Summary

Selank is a documented anxiolytic peptide with a short list of studied properties: anti-anxiety and mild nootropic activity, an intranasal form (drops), and dosing described in small clinical studies. This is an educational overview for a research context, not medical advice. If you work with neuropeptides, choose samples with confirmed purity and documented origin.

Longeva supplies Selank as a research substance; batches come with an independent COA, see the product page.

Sources

  1. Semax and Selank Inhibit the Enkephalin-Degrading Enzymes of Human Serum. Russian Journal of Bioorganic Chemistry. 2001. doi:10.1023/A:1011373002885
  2. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences. 2008. doi:10.1134/S0012496608040066
  3. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of Experimental Biology and Medicine. 2019. doi:10.1007/s10517-019-04588-9

The full list of sources with links, is in the monograph: Selank.